Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Active not recruiting 10Unknown 7Recruiting 6Completed 4Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 7

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Thoracic 7

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × lazertinib × Clear all
NCT05338619 2023-09-01

PLATINUM

Korea University Guro Hospital

Phase 2 Unknown
77 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Yonsei University

Phase 2 Unknown
129 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05716672 2023-02-08

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Pusan National University Hospital

Unknown
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Samsung Medical Center

Phase 2 Unknown
117 enrolled
Thoracic

Lung Neoplasms

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Seoul St. Mary's Hospital

Phase 2 Unknown
28 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05377788 2022-05-19

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Samsung Medical Center

Unknown
900 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05167851 2021-12-22

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Yonsei University

Phase 2 Unknown
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡